Northern, WI  11/21/2012 (BasicsMedia)  — Obesity is a major problem and a quick approval from US FDA for Obesity and other life saving drugs would make the life lot easier for the Pharma companies who are most of the times stuck and cannot launch their product in the market because of the regulatory hurdles. Approval of these drug would greatly benefit companies like Arena Pharmaceuticals Inc (NASDAQ:ARNA) and Vivus Inc (NASDAQ:VVUS) whose drugs named Belviq weight loss pill from Arena Pharmaceuticals and Qsymia from Vivus Inc were rejected by the regulator stating that it doesn’t meet the safety standards. Lately, the companies have done research and have rectified the short comings. It is also important for US FDA to improve the process of approving as it would need to cater to the needs of the patients who are suffering from deadly diseases and at a time when disease outbreak is fast and rampant.

Allan Coukell, deputy director of medical programs for the Pew Health Group said that “A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good,”
He also said that quick approval process would not only help companies but it would also help in curing infectious diseases more quickly and finding faster solutions to weight loss problems along with providing antibiotics in a timely manner to combat drug-resistant bacteria.

Companies would also be given an opportunity to present their case and would need to show that the benefits are more far compared to the risk involved for people who use these drugs. The Pharmaceutical Research and Manufacturers of America, a body which represents Pfizer Inc. (NYSE:PFE) and Merck & Co.(NYSE:MRK) along with other drug companies refused to comment on the issue and said that it would discuss with administration for finding out new ideas.

Arena’s Belviq and Vivus’s Qsymia are the only two drugs for weight loss which currently exist in the US market. Arena’s Belviq was the first drug which was approved by US FDA in 13 years. Both Arena Pharmaceuticals Inc and Vivus Inc said that they would conduct market studies at regular intervals to know the result of the drugs and they would also carry a warning label on the back of the drug.
Contrave is another pill which is being developed by Orexigen Therapeutics Inc. (NASDAQ:OREX) in collaboration with Osaka a Japan based Takeda Pharmaceutical Co. (4502).

Stock of Arena Pharmaceuticals Inc (NASDAQ:ARNA) was up by 5.72% to close at $8.50, Vivus Inc (NASDAQ:VVUS) was up by 0.58% to close at $10.33, Pfizer Inc (NYSE:PFE) was up by 0.84% to close at $23.86, Merk & Co (NYSE:MRK) was up by 0.63% to close at $43.07 and Orexigen Therapeutics, Inc (NASDAQ:OREX) was up by 6.27% to close at $4.24.

Disclaimer:  We have no position in any stock mentioned here.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.